Drug-coated balloons vs drug-eluting stents for the treatment of large native coronary artery disease. Meta-analysis of randomized controlled trials; Balón farmacoactivo frente a stent farmacoactivo para el tratamiento de la enfermedad coronaria de vaso grande. Metanálisis de ensayos clínicos aleatorizados
Fuente:
Zenodo
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Recurso digital |
| Published: |
Zenodo
2026
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866902173193863168 |
|---|---|
| author | Romero, J.A.S. Novelli, L. García, J.L. Montoro, S.H. Rubio, P. Gil, J.L.D. Martínez-Dolz, L. Santos, I.J.A. Cortese, B. Alfonso, F. García-García, H.M. Sanz-Sánchez, J. |
| author_facet | Romero, J.A.S. Novelli, L. García, J.L. Montoro, S.H. Rubio, P. Gil, J.L.D. Martínez-Dolz, L. Santos, I.J.A. Cortese, B. Alfonso, F. García-García, H.M. Sanz-Sánchez, J. |
| contents | Introduction and objectives: To compare the effects of drug-coated balloon (DCB) vs drug-eluting stent (DES) in patients presenting with de novo large vessel coronary artery disease (CAD). Methods: We conducted a systematic research of randomized controlled trials comparing DCB vs DES in patients with de novo large vessel CAD. Data were pooled by meta-analysis using a random-effects model. The prespecified primary endpoint was target lesion revascularization (TLR). Results: A total of 7 trials enrolling 2961 patients were included. The use of DCB vs DES was associated with a similar risk of TLR (OR, 1.21; 95%CI, 0.44-3.30; I2 = 48%), all-cause mortality (OR, 1.56; 95%CI, 0.94- 2.57; I2 = 0%), cardiac death (OR, 1.65; 95%CI, 0.90-3.05; I2=0%), myocardial infarction (OR, 0.97; 95%CI, 0.58-1.61; I2 = 0%), major adverse cardiovascular adverse (OR, 1.19; 95%CI, 0.74-1.90; I2 = 13.5%) and late lumen loss (standardized mean difference [SMD], -0.35; 95%CI, -0.74 to 0.04; I2 = 81.4%). However, the DCB was associated with a higher risk of target vessel revascularization (OR, 2.47; 95%CI, 1.52-4.03; I2 = 0%) and smaller minimal lumen diameter during late follow-up (SMD, -0.36; 95%CI, -0.56 to -0.15; I2 = 34.5%). Nevertheless, prediction intervals included the value of no difference for both outcomes. Conclusions: In patients with de novo large vessel CAD the use of DCB vs DES is associated with a similar risk of TLR. However, the DES achieves better late angiographic results. © 2025 Sociedad Española de Cardiología. Published by Permanyer Publications. This is an open access journal under the CC BY-NC-ND 4.0 license. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_24875_RECICE_M25000527 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Drug-coated balloons vs drug-eluting stents for the treatment of large native coronary artery disease. Meta-analysis of randomized controlled trials; Balón farmacoactivo frente a stent farmacoactivo para el tratamiento de la enfermedad coronaria de vaso grande. Metanálisis de ensayos clínicos aleatorizados Romero, J.A.S. Novelli, L. García, J.L. Montoro, S.H. Rubio, P. Gil, J.L.D. Martínez-Dolz, L. Santos, I.J.A. Cortese, B. Alfonso, F. García-García, H.M. Sanz-Sánchez, J. Coronary artery disease Drug-coated balloon Drug-eluting stent Introduction and objectives: To compare the effects of drug-coated balloon (DCB) vs drug-eluting stent (DES) in patients presenting with de novo large vessel coronary artery disease (CAD). Methods: We conducted a systematic research of randomized controlled trials comparing DCB vs DES in patients with de novo large vessel CAD. Data were pooled by meta-analysis using a random-effects model. The prespecified primary endpoint was target lesion revascularization (TLR). Results: A total of 7 trials enrolling 2961 patients were included. The use of DCB vs DES was associated with a similar risk of TLR (OR, 1.21; 95%CI, 0.44-3.30; I2 = 48%), all-cause mortality (OR, 1.56; 95%CI, 0.94- 2.57; I2 = 0%), cardiac death (OR, 1.65; 95%CI, 0.90-3.05; I2=0%), myocardial infarction (OR, 0.97; 95%CI, 0.58-1.61; I2 = 0%), major adverse cardiovascular adverse (OR, 1.19; 95%CI, 0.74-1.90; I2 = 13.5%) and late lumen loss (standardized mean difference [SMD], -0.35; 95%CI, -0.74 to 0.04; I2 = 81.4%). However, the DCB was associated with a higher risk of target vessel revascularization (OR, 2.47; 95%CI, 1.52-4.03; I2 = 0%) and smaller minimal lumen diameter during late follow-up (SMD, -0.36; 95%CI, -0.56 to -0.15; I2 = 34.5%). Nevertheless, prediction intervals included the value of no difference for both outcomes. Conclusions: In patients with de novo large vessel CAD the use of DCB vs DES is associated with a similar risk of TLR. However, the DES achieves better late angiographic results. © 2025 Sociedad Española de Cardiología. Published by Permanyer Publications. This is an open access journal under the CC BY-NC-ND 4.0 license. |
| title | Drug-coated balloons vs drug-eluting stents for the treatment of large native coronary artery disease. Meta-analysis of randomized controlled trials; Balón farmacoactivo frente a stent farmacoactivo para el tratamiento de la enfermedad coronaria de vaso grande. Metanálisis de ensayos clínicos aleatorizados |
| topic | Coronary artery disease Drug-coated balloon Drug-eluting stent |
| url | https://doi.org/10.24875/RECICE.M25000527 |